F109 Side Effects May Include: Illustrative Cases of Dermatologic Adverse Events
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Dermatologists are frequently called upon to diagnose and manage patients with suspected drug rashes. With the pace of new medication development, it is important but difficult to keep up with the spectrum of side effects relevant to dermatology. This case-based interactive session will explore dermatologic adverse events. This will include cutaneous adverse reactions of non-dermatologic medications, as well as rare potential side effects of medications commonly prescribed by dermatologists. Cases will be selected that illustrate the clinical presentation, differential diagnosis, workup, and management of a variety of cutaneous adverse reactions and dermatologic drug side effects. This activity has been approved by the American Board of Dermatology (ABD) for up to 20 Continuous Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.
LEARNING OBJECTIVES
Recognize different forms of cutaneous adverse reactions and uncommon side effects of dermatologic medications.
Manage patients with dermatologic adverse reactions and develop evaluation and treatment plans based on reaction type.
Determine the most likely causative medications for specific cutaneous adverse reactions.
SCHEDULE
8:00 PM
Medication Side Effects in Children
Andrea Waldman, MD, FAAD
8:30 PM
Medication Safety in Older Adults
Daniel Charles Butler, MD, FAAD
9:00 PM
Side Effects May Include...
Cindy Owen, MD, FAAD
9:30 PM
Side Effects in Skin Cancer Patients
Margaret (Molly) Moye, MD, FAAD
SPEAKERS
Daniel Charles Butler, MD, FAAD
Margaret (Molly) Moye, MD, FAAD
Cindy Owen, MD, FAAD
Andrea Waldman, MD, FAAD
SPEAKER DISCLOSURES
Daniel Charles Butler, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Galderma – Advisory Board(Fees); Leo Pharma Inc – Advisory Board(Fees); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Advisory Board(Honoraria);
Margaret (Molly) Moye, MD, FAAD
Forefront Dermatology – Stockholder(Stock);
Cindy Owen, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Acrotech Biopharma Inc – Investigator(Grants/Research Funding); Amgen – Investigator(Grants/Research Funding); Bausch Health – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Investigator(Grants/Research Funding); Celgene – Investigator(Grants/Research Funding); Connect Biopharma LLC – Investigator(Grants/Research Funding); Dermavant Sciences, Inc. – Investigator(Grants/Research Funding); Eli Lilly and Company – Investigator(Grants/Research Funding); Forte – Investigator(Grants/Research Funding); Galderma USA – Investigator(Grants/Research Funding); Horizon Therapeutics USA, Inc – Investigator(Grants/Research Funding); Incyte – Investigator(Grants/Research Funding); janssen – Investigator(Grants/Research Funding); Novartis – Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding);
Andrea Waldman, MD, FAAD
No financial relationships exist with ineligible companies.